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Antioxidant enzymep66Shc, the growth factor adaptor protein, can have a substantial impact on mitochondrial metabolism
through regulation of cellular response to oxidative stress. We investigated relationships between the extent
of p66Shc phosphorylation at Ser36, mitochondrial dysfunctions and an antioxidant defense reactions in
ﬁbroblasts derived from ﬁve patients with various mitochondrial disorders (two with mitochondrial DNA
mutations and three with methylglutaconic aciduria and genetic defects localized, most probably, in nuclear
genes). We found that in all these ﬁbroblasts, the extent of p66Shc phosphorylation at Ser36 was
signiﬁcantly increased. This correlated with a substantially decreased level of mitochondrial superoxide
dismutase (SOD2) in these cells. This suggest that SOD2 is under control of the Ser36 phosphorylation status
of p66Shc protein. As a consequence, an intracellular oxidative stress and accumulation of damages caused
by oxygen free radicals are observed in the cells.Biomembranes, Department of
ur 3 St., 02-093Warsaw, Poland.
Wieckowski).
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The 66-kDa isoform of ShcA, the growth factor adapter protein
(p66Shc), and its relevance to cell signaling have attracted major
interest in aging research. In 1999, Pellici at al. [1] discovered that
ROS-mediated signals, generated by p66Shc, favored apoptosis at the
cellular and aging at the organismal levels, leading to tissue damage.
As a result, p66Shc was proposed to regulate mammalian life span.
These authors found that the life span of transgenic mice lacking
p66Shc was longer by 30–40% compared to wild-type animals.
Interestingly, prolongation of the life span corresponding to the
ablation of p66Shc gene had no pathological consequences [1]. Taking
into account the free radical theory of aging [2], it can be assumed that
this protein can be involved in the cellular response to oxidative stress
and clearly explains signiﬁcantly enhanced resistance to oxidative
stress of transgenic animals lacking p66Shc [1,3]. Three proteins of the
ShcA family, p66Shc, p52Shc and p46Shc, have been identiﬁed up tonow [4]. Two mRNAs derive from ShcA gene: p66shc and p46shc/
p52shc, the latter one being translated into 2 proteins, p46shc and
p52shc, after alternative translation start sites [4,5].
Each protein of the ShcA subfamily (p66Shc, p52Shc and p46Shc)
contains three functionally identical domains: C terminal Src-homology
domain (SH2), central collagen-homologydomain (CH1) andN-terminal
phosphotyrosine-bindingdomain (PTB). p66Shc contains additionallyN-
terminal proline-rich collagen-homology domain (CH2) with a serine
phosphorylation site (Ser36) [3,4].Numerous studies havedemonstrated
that p66Shc is phosphorylated mainly at this residue in response to UV
exposure or H2O2 treatment [1,6]. Such phosphorylation is mediated by
oneof serine–threonine kinases, proteinkinaseCβ (PKCβ), and this event
induces a signaling cascade leading to apoptosis [7]. p66Shc phosphor-
ylated at Ser36 (Ser36-P-p66Shc) is a substrate of prolyl isomerase Pin1
and, after isomerisation, it is dephosphorylated by phosphatase A2
(PPA2) [7]. This sequence of events triggers translocation of p66Shc from
the cytosol to mitochondria [7]. Recently, we have demonstrated that
p66Shc can also be found in plasma membrane-associated membrane
(PAM) andmitochondria-associatedmembrane (MAM) fractions [8–10].
Intracellular distribution of p66Shc seems to be age dependent. MAM
fraction isolated from livers of old mice was signiﬁcantly enriched in
p66Shc. Moreover, Ser36-P-p66Shc in the crude mitochondrial fraction
(containing theMAM fraction) wasmore abundant in older mice and its
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p66Shc, once translocated to mitochondria and/or MAM fraction,
perturbs their structure and function, e.g., by modifying mitochondrial
Ca2+ responses and the mitochondrial metabolism [1,11,12].
The signaling pathway described by Pinton et al. [7] is triggered by
extracellular oxidative stress (e.g. H2O2 treatment) and involves
p66Shc phosphorylation at Ser36. During aging, gradually accumulat-
ed mitochondrial and nuclear DNA damages and dysfunctions of the
antioxidant defense system lead to an increase of intracellular reactive
oxygen species (ROS) level; this in turn activates PKCβ-dependent
phosphorylation of p66Shc and initiates a vicious circle of ROS produc-
tion [13]. A similar situation may occur in the case of mitochondrial
dysfunction associated with inherited disorders of oxidative phos-
phorylation (OXPHOS). The frequency of such mitochondrial diseases
is relatively high (1:5000). They are present in neonates, infants,
children and adults; they are progressive and not treatable [14,15].
The major pathogenic mechanism is considered to be a shortage in
cellular energy supply. The inﬂuence of the pathological oxidative
stress on the course of mitochondrial disorders and on the antioxidant
defense balance has not been elucidated in detail. A higher rate of
ROS production by mitochondria has already been described in many
genetic mitochondrial defects [16]. The superoxide anion radical
(O2●−) is the main reactive oxygen species produced by mitochondria.
The defects of respiratory chain caused by genetically inherited
mutations in mitochondrial or nuclear DNA, leading to isolated or
combined defects in respiratory chain complexes, may result in
signiﬁcantly elevated superoxide production. These extra ROS addi-
tionally potentiate mitochondrial damage and, in consequence, cause
accelerated ROS production.
In the present work, we investigated whether mitochondrial
dysfunctions of different genetic origin lead to an increased
phosphorylation of p66Shc at Ser36, modiﬁcation of the intracellular
antioxidant defense system and stress-induced protein carbonylation.r
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2.1. Ethics
The study was carried out in accordance with the Declaration of
Helsinki of the World Medical Association and was approved by the
Committee of Bioethics at the Children's Memorial Health Institute.
Informed consent was obtained from the parents before any biopsy or
molecular analysis was performed.Ta
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To study phosphorylation of p66Shc at Ser36 in response to
intracellular oxidative stress, ﬁve patients with deﬁned mitochon-
drial disorders were recruited. The patients presented different
clinical phenotypes and various OXPHOS abnormalities in muscle
biopsies and ﬁbroblast cultures that were derived from these
patients. The ﬁbroblast cultures were started from patients at the
age of 4 months, 6 months, 3 months, 3 weeks and 14 months,
respectively. At the time of the mitochondrial disease suspicion,
the patients presented severe mitochondrial encephalopathy (P1),
Leigh disease, deafness and retinitis pigmentosa (P2), progressive
fatal mitochondrial cardiomyopathy (P3), severe neonatal lactic
acidosis (P4) and hypertrophic cardiomyopathy with neutropenia
(P5). Hyperlactatemia and hyperlactaturia were present in all
patients. Patients 3, 4 and 5 showed additionally increased excretion
of methylglutaconic acid in urine.
The probability level ofmitochondrial disease determined according
to the Nijmegen scale was above the probability threshold respectively:
8, 8, 6, 7 and 4. The overall patient characteristics is shown in Table 1.
954 M. Lebiedzinska et al. / Biochimica et Biophysica Acta 1797 (2010) 952–9602.3. Fibroblast cultures
Human skin ﬁbroblasts were grown from explants of skin biopsies
of one healthy individual and ﬁve patients in Dulbecco modiﬁed
Eagle's medium with glucose (4.5 g/l), 5 mM sodium pyruvate and
2mM L-glutamine (Sigma Aldrich), supplemented with 10% (v/v) fetal
bovine serum (Gibco), and 1.2% antibiotic, antimycotic solution (Sigma
Aldrich) in an atmosphere of 5% (v/v) carbon dioxide in air at 37 °C.
Additionally, NHDF neonatal dermal ﬁbroblasts, Cat. n. CC-2509, and
NHDF adult dermalﬁbroblasts, Cat. n. CC-2511, from Lonzawere used as
control healthyﬁbroblasts. The cellswere grown in75 cm2 cultureﬂasks
and used within 6 days after reaching conﬂuence.
2.4. Hispidin treatment
Dulbecco modiﬁed Eagle's medium was supplemented with 5 μM
hispidin and the cells were cultured for 48 h. In the case of long
treatment (28 days), the growth medium supplemented with 3 μM
hispidin was changed every two days. The passages (from fourth to
eight) were also made in the presence of 3 μM hispidin.
2.5. Enzymatic measurements
Spectrophotometric assays in post-nuclear supernatants obtained
from skeletal muscle biopsies and ﬁbroblast cell cultures were used for
the measurement of complex I (NADH:ubiquinone oxidoreductase,Fig. 1. Bioenergetic parameters (mtΔΨ, respiratory chain activity) and ROS production
(A)Mitochondrial membrane potential in cultured ﬁbroblasts. Data shown aremeans±SD, *
shown are means±SD, *pb0.05 (n=6) versus control. (C) Cytosolic superoxide (cO2●−), (D
cultured ﬁbroblasts. Data shown are means±SD, *pb0.05 (n=6) versus control for each protenone-sensitive), complex II (succinate:ubiquinone oxidoreductase,
malonate-sensitive), complex III (ubiquinone:cytochrome c oxidoreduc-
tase, antimycin A-sensitive), complex IV (cytochrome c oxidase) and
citrate synthase as described previously [17]. Activities of the respiratory
complexes were expressed as the ratio to the activity of citrate synthase
in order to avoid the inﬂuence of different amounts of mitochondria in
the material under investigation. Protein content in post-nuclear super-
natants was determined by the method of Lowry et al. [18].
2.6. Samples preparation for Western blot
Cell pellets were resuspended in cold lysis buffer (50 mM Tris pH
7.5, 150 mM NaCl, 1% Triton, 0.1% SDS, 1% sodium deoxycholate)
containing inhibitors of proteases (1 mM PMSF and the protein
protease inhibitor cocktail) and phosphatases (1 mM Na3VO4, 10 mM
NaF). Samples were incubated on ice for 15 min and centrifuged at
14,000×g for 20 min at 4 °C to remove insoluble material. Protein
concentration in lysates was determined using Bradford method.
Samples for SDS–PAGE were denatured in reducing Laemmli loading
buffer at 45 °C or 95 °C for 5 min, depending on the antibody.
2.7. Western blotting
Cell lysates (25 – 50 μg protein) were separated electrophoretically
in 8% or 10% SDS–polyacrylamide gel (BioRad) and transferred onto
PVDF membrane (BioRad). Membranes were blocked using 2% non–fat(cytosolic and mitochondrial O2●− and H2O2) in control and patients' ﬁbroblasts.
pb0.05 (n=6) versus control. (B) Respiratory chain activity in cultured ﬁbroblasts. Data
) mitochondrial superoxide (mtO2●−) and (E) hydrogen peroxide (H2O2) production in
arameter.
955M. Lebiedzinska et al. / Biochimica et Biophysica Acta 1797 (2010) 952–960milk in TBS buffer containing 0.01% Tween 20 (Sigma Aldrich) for 1 h.
Proteins were detected with anti-Shc and anti-Ser36-P-p66Shc mono-
clonal antibodies (1:1000, Abcam), anti-SOD1 rabbit polyclonal anti-
body (1:5000, Santa Cruz), anti-SOD2 goat polyclonal antibody (1:500,
Santa Cruz), anti-catalase monoclonal antibody (1:1000, Santa Cruz)
and anti-actin antibody (1:10000, Abcam) followed by secondary HRP–
conjugated antibodies (1:5000) (Santa Cruz).2.8. Measurement of mitochondrial membrane potential (mtΔΨ)
Fibroblasts grown in 12-well plates were washed twice with PBS
to remove the medium and then incubated in the presence of 10 µM
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine
iodide (JC-1) in PBS containing 5 mM glucose for 10 min at 37 °C. The
cells were washed twice with PBS and the green and red ﬂuorescence
was recorded in a microplate reader (Inﬁnite M200, Tecan, Austria),
respectively, at 485 nm excitation/520 nm emission and at 535 nm
excitation/635 nm emission wavelengths.2.9. Measurement of respiratory chain activity
Fibroblasts grown in 12-well plates were washed twice with PBS
and then incubated in PBS containing 5 mM glucose and 6 µM
resosurine and the ﬂuorescence was recorded immediately thereafter
in a microplate reader at 510 nm excitation and 595 nm emissionFig. 2. Levels of p46Shc, p52Shc, p66Shc and its Ser36-fosphorylated form in control and pati
p46Shc) and Ser36-P-p66Shc. Samples (15–30 μg protein/lane) from a control volunteer and
(B) Densitometry analysis of Shc protein expression. (C) Densitometric analysis of Ser36-P
individual proteins were calculated as a ratio to α-actin. The values are means from two inwavelengths. To determine the unspeciﬁc reaction, the cells were
preincubated for 15 min with 2 mM KCN added to medium.2.10. Measurement of cytosolic superoxide (cO2
●− ) production
Fibroblasts grown in 12-well plates were incubated for 20 min at
37 °C in the presence of 0.5 µM dihydroethidium (DHE) in PBS
containing 5 mM glucose. The cells were washed twice with PBS, and
the ﬂuorescence was recorded in a microplate reader at 535 nm
excitation and 635 nm emission wavelengths.2.11. Measurement of mitochondrial superoxide (mtO2
●−) production
Fibroblasts grown in 12-well plates were incubated for 10 min at
37 °C in the presence of 2.5 µM MitoSox in PBS containing 5 mM
glucose. The cells were washed twice with PBS and the ﬂuorescence
was recorded in amicroplate reader at 510-nm excitation and 595-nm
emission wavelengths.2.12. Measurement of H2O2 production
The rate of H2O2 production was measured with the ROS-sensitive
ﬂuorescent probe 5-(and 6)-chloromethyl-2′,7′-dichlorohydroﬂuor-
escein diacetate (CM-H2DCFDA). The cells grown in 12-well plates
were treated with 2 μM CM-H2DCFDA, and the ﬂuorescence wasents' ﬁbroblasts. (A) Representative Western blots of Shc proteins (p66Shc, p52Shc and
5 patients were separated on 8% gel (for Shc proteins) or 10% gel (for Ser36-P-p66Shc).
-p66Shc level. (D) Calculated ratio of Ser36-P-p66Shc to p66Shc protein. The levels of
dependent experiments.
956 M. Lebiedzinska et al. / Biochimica et Biophysica Acta 1797 (2010) 952–960recorded in a microplate reader for 30 minutes at 495 nm excitation
and 520 nm emission wavelengths.
2.13. Detection of protein modiﬁcation by oxygen free radicals
The level of oxidized proteins was estimated with the use of the
OxyBlot Protein Oxidation Detection Kit (Chemicon). Aliquots of 25 μg
protein were separated on 10% SDS–polyacrylamide gel and the
standard protocol of the manufacturer was followed.
2.14. Statistical analysis
Differences in band densities were analyzed using NIH ImageJ
software. Data obtained from the Tecan microplate reader were cal-
culated using Microsoft™ Excel 2005 and analyzed for signiﬁcance by
Student's t-test.
3. Results
To study phosphorylation of p66Shc at Ser36 in the situation of
intracellular oxidative stress, we used ﬁbroblast culture from ﬁve
patients with genetically deﬁnedmitochondrial defects. The diagnosis
of mitochondrial disease depended on the clinical phenotype,
biochemical and enzymatic studies of muscle biopsies and DNA
analysis. There were one severely affected infant with isolated
complex I deﬁciency due to the mitochondrial DNA (mtDNA)
mutation in ND3 subunit (P1), one infant with combined OXPHOS
defect due to a tRNALeu1 rare mutation (P3) and three children with
multi-organ mitochondrial disorders and methylglutaconic aciduria,
among them one girl (P2) and two brothers with Barth syndrome (P4
and P5). The patients' characteristic is presented in Table 1. The
expression of relevant OXPHOS abnormalities in some patients'Fig. 3. Expression of SOD1, SOD2 and catalase in control and patients' ﬁbroblasts with mitoc
(B) Expression proﬁle of mitochondrial superoxide dismutase (SOD2). (C) Expression
polyacrylamide gel. Bar charts show the levels of antioxidant enzymes calculated as a ratioﬁbroblasts was previously detected by spectrophotometric measure-
ment of respiratory chain complex I-IV activities and conﬁrmed by
BN–PAGE and SDS (not shown).
3.1. Metabolic characterization of patient ﬁbroblasts
To determine whether a mitochondrial dysfunction was present in
the studied ﬁbroblast cultures, mitochondrial membrane potential
(mtΔΨ) and respiratory chain activity were measured. The measure-
mentofmtΔΨwith theuseof aﬂuorescentprobe JC-1 showedadecrease
in the proton-motive force in mitochondria of patients' ﬁbroblasts. In
three cases (P1, P2 and P3),mtΔΨwas decreased by 10–20%, while in P4
and P5 it was decreased by as much as 65–70% (Fig. 1A). In three lines of
ﬁbroblasts (P1, P2 and P3), the activity of the respiratory chain was
reduced by ∼20%. The respiratory chain activity in P4 and P5 was only
slightly decreased (Fig. 1B). Lower mtΔΨ and decreased activity of the
respiratory chain suggest that mitochondria were coupled and that the
observed decreased electron ﬂow through the respiratory chain could be
a result of OXPHOS dysfunction. Moreover, evaluation of intracellular
ROS production conﬁrmed the occurrence of increased intracellular
oxidative stress in the studied cells. Both cytosolic and mitochondrial
ROS generation by ﬁbroblasts of patients P1, P2 and P5 was increased
(Fig. 1C, D), while in ﬁbroblasts from P4 only mitochondrial superoxide
generationwas enhanced. The rate of H2O2 productionwas higher in P1
and was even doubled in P2 and P3 (Fig. 1E). Oxidative stress in these
cells was also demonstrated by increased level of protein carbonylation
(Supplementary Fig. 1). This indicated a proper selection of thematerial
for these studies. Additionally, we compared control cell line (C) with
human neonatal dermal ﬁbroblasts (Fn) and human adult dermal
ﬁbroblasts (Fa). These results show that the control cell line (C) and
neonatal dermal ﬁbroblasts (Fn) have similar mitochondrial bioener-
getics parameters and ROS production. The adult dermal ﬁbroblastshondrial dysfunction. (A) Expression proﬁle of cytosolic superoxide dismutase (SOD1).
proﬁle of catalase. Cell lysates (40 μg protein/lane) were separated on 10% SDS–
to α-actin. The values are means from two independent experiments.
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respiratory chain activity (Supplementary Fig. 2). This indicates
necessity of the use of cell lines derived from the individuals at the
similar age in such comparative studies.
3.2. Evaluation of p66Shc level and Ser36 phosphorylation status of
p66Shc in control and patients' ﬁbroblasts
To estimate changes in the levels of p66Shc and Ser36-P-p66Shc,
we ﬁrst measured the level of three ShcA proteins (p46Shc, p52Shc
and p66Shc) and determined the ratios of p66Shc/p52Shc and
p66Shc/p46Shc in control and patients' ﬁbroblasts. The level of all
ShcA proteins in the control and in all ﬁve patients' ﬁbroblasts was
similar (Fig. 2A and B) Interestingly, in all patients' cells, the level of
Ser36-phosphorylated p66Shc was dramatically elevated without anyFig. 4. Effect of long-term hispidin treatment on Ser36-phosphorylation status of
p66Shc in control and patients' ﬁbroblasts with mitochondrial dysfunction. Fibroblasts
were treated for 28 days with 3 μM hispidin as described in Materials and methods.
(A) Bar charts and R values show the ratio of Ser36-P-p66Shc to the p66Shc protein. The
values are means from two independent experiments. (B) The ratio of Ser36-P-p66Shc
to the p66Shc. The values are means from all patients±SD, *pb0.05 (n=5) versus
control.external stimulus (like H2O2 treatment) (Fig. 2A and C). Additionally,
the ratio of Ser36-P-p66Shc to the p66Shc conﬁrmed a drastic shift in
the extent of p66Shc phosphorylation at Ser36 (Fig. 2D). Comparison
of control cell lines showed similar low level of Ser36 phosphorylated
p66Shc (Supplementary Fig. 3). This points to an activation of PKCβ
and p66Shc phosphorylation as a response to the mitochondrial
defect-related enhanced oxidative stress in these cells. Antimycin A-
induced oxidative stress in neonatal dermal ﬁbroblasts (Fn) (repre-
sented as an augmented cytosolic and mitochondrial superoxide
production) is connected with the increased phosophorylation status
of p66Shc (Supplementary Figs. 4 and 5). Mitochondria-targeted
antioxidant SkQ partially protects against antimycin A effect, what
indicates direct relation between oxidative stress and Ser36 phos-
phorylation of p66Shc (Supplementary Fig. 5).
3.3. Antioxidant enzyme levels in patients' ﬁbroblasts
Intracellular oxidative stress may modify the cellular antioxidant
defense system by p66Shc phosphorylation at Ser36. We determined
the expression proﬁle of cytosolic (Cu/ZnSOD, SOD1) and mitochon-
drial (MnSOD, SOD2) superoxide dismutases and catalase (Cat). We
observed a signiﬁcant decrease of SOD2 level and unchanged SOD1
level in ﬁbroblasts of all ﬁve patients (Fig. 3 B and A). Catalase levels in
the cells with mitochondrial dysfunction were variable. In P3
ﬁbroblasts the level seemed to be unchanged; in ﬁbroblasts of two
patients (P1 and P2) it was lower, whereas in ﬁbroblasts of P4 and P5
it was greatly increased (Fig. 3C). Supplementary Fig. 3 shows
antioxidant enzyme levels in control cell lines.
3.4. Inhibition of the PKCβ pathway and its effect on ROS production and
mitochondrial parameters
To check if the inhibition of p66Shc phosphorylation at Ser36 could
attenuate intracellular oxidative stress, we incubated the ﬁbroblastsFig. 5. Effect of long-term hispidin treatment on cytosolic superoxide production in
control and patients' ﬁbroblasts cultured conventionally (C) or treated (+H) for
28 days with 3 μM hispidin as described in Materials and methods. Data shown are
means±SD, *pb0.05 (n=6) versus control for each parameter.
Fig. 6. Effect of long-term hispidin treatment on SOD1 and SOD2 expression in control and patients' ﬁbroblasts. (A) Expression proﬁle of cytosolic superoxide dismutase;
(B) mitochondrial superoxide dismutase in control and patients' ﬁbroblasts. Fibroblasts were cultured conventionally (C) or treated (+H) for 28 dayswith 3 μMhispidin as described
in Materials and methods. Bar charts show the level of antioxidant enzymes calculated as a ratio to α-actin. The values are means from two independent experiments.
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p66Shc phosphorylation (Supplementary Fig. 2) and had no effect on
ROS production and onmitochondrial parameters (data not shown) in
both control and patients' ﬁbroblasts. The long-term effect obtained
by incubation with 3 μM hispidin for 28 days resulted in the reduced
pool of Ser36-P-p66Shc (Fig. 4A). Calculated mean values from all
patients show signiﬁcant (∼50%) decrease in the phosphorylation
status of p66Shc after hispidin treatment (Fig. 4B). This was correlated
with a decrease of cytosolic superoxide production (cO2●−) (Fig. 5). At
the same time, the mitochondrial superoxide production (mtO2●−)
was not signiﬁcantly modiﬁed. Moreover, mitochondrial bioenergetic
parameters (mtΔΨ and the respiratory chain activity) in patients'
ﬁbroblasts were also changed insigniﬁcantly by hispidin treatment.
Only in ﬁbroblasts from the healthy volunteer hispidin treatmentFig. 7. Effect of long-term hispidin treatment on the degree of protein carbonylation a
conventionally (C) or treated (+H) for 28 days with 3 μMhispidin as described in Materials a
and methods. (B) Hydrogen peroxide production in cultured ﬁbroblasts. Data shown are mincreased mtΔΨ, simultaneously decreasing the respiratory chain
activity (data not shown).
3.5. Effect of the inhibition of p66Shc phosphorylation on the levels of
SOD1 and SOD2
To ﬁnd out whether the increased level of p66Shc phosphorylated
at Ser36 affects the antioxidant defense system, we studied the effect
of hispidin on the expression proﬁles of SOD1 and SOD2.We observed
that, after inhibition of Ser36-p66Shc phosphorylation by long-term
hispidin treatment, SOD1was up-regulated in the control and in three
lines of patients' ﬁbroblasts (P2, P3 and P5), whereas SOD2 was
elevated in P3 and P4 and slightly elevated in P2 and P5. In the control
cells, SOD1 level was considerably increased by the hispidin treatmentnd H2O2 production in control and patients' ﬁbroblasts. Fibroblasts were cultured
ndmethods. (A) Level of carbonylated proteins was estimated as described in Materials
eans±SD, *pb0.05 (n=6) versus control for each parameter.
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condition, we observed an increase in protein carbonylation (Fig. 7A)
probably as a result of increased H2O2 production (Fig. 7B).
4. Discussion
This is the ﬁrst report showing that mitochondrial dysfunction-
related intracellular oxidative stress can trigger phosphorylation of
p66Shc at Ser36. As a model of elevated intracellular oxidative stress,
we used ﬁbroblasts derived from ﬁve patients with deﬁned
mitochondrial disorders. Our results clearly demonstrate remarkable
abnormalities in all examined bioenergetic and ROS parameters
regardless of the origin of genetic defects in the patients' cells. All
ﬁbroblasts derived from the patients showed a signiﬁcant decrease in
mtΔΨ and an increase in ROS production. We observed some
differences between the patients. The changes were less expressed
in the patient with mtDNA tRNALeu1 mutation (P3). Possible
elimination of the pathogenic mutation load during ﬁbroblast
cultivation (below the heteroplasmy threshold value) were not
assessed and might explain this ﬁnding. Patients 4 and 5, two
brothers with Barth syndrome, differed from other patients by
showing respiratory chain activity at the normal range. Mitochondrial
dysfunction in Barth syndrome may be caused by abnormal
cardiolipin metabolism and its inﬂuence on assembly of respiratory
chain complexes and carriers [19,20]. Reduced mitochondrial mem-
brane potential and unaffected mitochondrial ATP formation were
reported earlier in Barth patient lymphoblasts [21].
Since p66shc protein was related to the cellular response to
oxidative stress, its high level was correlated with the increased ROS
production [1,8]. We demonstrated that, although the expression of
p66Shc was unchanged, Ser36-P-p66Shc/p66Shc ratio was highly
elevated in all studied patients' ﬁbroblasts. The presented results
clearly indicate that in ﬁbroblasts with mitochondrial dysfunction,
SOD2 and SOD1 levels can depend on the p66Shc phosphorylation
state. This is in agreement with the recent reports describing similar
observations in diabetes, Alzheimer disease, ethanol-induced liver
damage and hypoxia/reoxygenation damage of hepatocytes [22–25].
A lower capacity of the antioxidant defense can be a reason for
oxidative damage manifested for example by higher protein carbon-
ylation [26]. One of the factors interacting with p66Shc and
controlling mammalian intracellular metabolism and antioxidant
defense is FKHRL1 (FOXO3a), a transcription factor belonging to the
FoxO family and relevant to energy metabolism, proliferation and cellFig. 8. Scheme showing the effect of p66Shc phosphorylated at Ser3death [27,28]. In response to the mitochondrial dysfunction-related
increased intracellular oxidative stress, high Ser36-phosphorylation
status of p66Shc promotes an additional increase of intracellular ROS
generation. This results in the recruitment of Akt/PKB to the p66Shc-
FOXO3a complex and direct inactivation of FOXO transcription factors
by their phosphorylation. Thus, decreased level of antioxidant defense
and higher ROS production can be observed (Figs. 1 and 3). Moreover,
decrease of the p66Shc phosphorylation at Ser36 caused by hispidin, a
PKCβ inhibitor, is accompanied by positive modulation of the
mitochondrial antioxidant defense in patients' ﬁbroblasts (Fig. 4 and
Supplementary Fig. 6). This mechanism is supported by our observa-
tions that SOD1 (in control, P2 and P3) and SOD2 (in P2, P3, P4 and P5)
levels were up-regulated after inhibition of Ser36-p66Shc phosphor-
ylation (Fig. 6). The up-regulated level of SOD1 (in three cases out of
ﬁve investigated) and SOD2 (in four cases out of ﬁve) in the response
to hispidin treatment contributes to an increased production of H2O2
and, most probably, to an increased protein carbonylation in the
treated cells (Fig. 7). Increased protein carbonylation in response to
H2O2 addition to cell cultures or enhanced intracellular H2O2
production has already been reported [26,29].
Hispidin treatment, apart from improving the antioxidant defense,
was manifested in control ﬁbroblasts by an increase in mtΔΨ and a
decrease in the rate of respiration. This shows that mitochondria in
the treated cells became more tightly coupled. This can explain
previously reported higher calcium uptake by ﬁbroblasts treated with
hispidin [7]. Increased mtΔΨ is probably a reason of an increased
mtO2●−production observed in control ﬁbroblasts in response to
hispidin treatment. Mitochondrial parameters in patients' ﬁbroblasts
remained unchanged because hispidin cannot “repair” genetically
caused mitochondrial defects.
A growing piece of evidence indicates that low level of p66Shc or
its complete ablation (what determines a low level or the absence of
Ser36-P-p66Shc) protects against numerous age-related disorders
and can partially prevent pathologies caused by ROS. Looking for
strategies that could minimize the cellular effect of p66Shc phos-
phorylation at Ser36, it is necessary to remember that p66Shc also
plays an important role in signal transduction pathways and regulates
the crucial cellular Ras/MAPK kinase cascade [30]. However, in
contrast to the data reported by Migliaccio et al. [1] that the lack of
p66Shc protein does not result in any abnormalities, some new data
have recently appeared on a low level of p66Shc in autoimmunolo-
gical disorders [31]. It was found that p66Shc knockout mice
developed an age-related autoimmune disease characterized by6 on the intracellular oxidative stress and antioxidant defense.
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antibodies and T-lymphocytes. In turn, the immunologic tolerance
was impaired and resulted in autoimmunological aggression observed
in p66Shc knockout mice [31]. In the light of these data, administra-
tion of mitochondrialy targeted antioxidants seems to be a promising
and safe way to stop the vicious circle of p66Shc phosphorylation at
Ser36, responsible for the pro-oxidant properties of p66Shc (see
Fig. 8). This may open new possibilities for pharmacological inter-
ventions in case of pathological intracellular oxidative stress by such
compounds (as SkQ and mitoQ) with documented therapeutic effect
[32–34].
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